Skip to content

ICBT for Antenatal Depression

Psychological Treatment Via the Internet for Antenatal Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02366429
Enrollment
60
Registered
2015-02-19
Start date
2015-02-28
Completion date
2016-03-31
Last updated
2016-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antenatal Depression

Brief summary

Randomized controlled trial evaluating an Internet-delivered Cognitive Behavioral Therapy (ICBT) adapted for pregnant women suffering from antenatal depression. The ICBT-program will be added to treatment as usual (TAU) and compared to TAU only. Participants (n=60) are recruited from all over Sweden (only Swedish citizens can participate) and are assessed and treated on a distance via a secure web platform and telephone.

Detailed description

In order to evaluate feasibility and effectiveness of an ICBT-program for antenatal depression that will be used in a larger clinical trial, the current RCT (n=60) will be performed and act as a pilot for the main study. Participants will all be receiving the regular treatment (TAU) provided at their antenatal clinic and other health care instances. Half of them will be randomized to an add-on of a previously established 10-week long ICBT-program for depression in general, now adapted for pregnant women. The other half will receive TAU during 10 weeks and then freely decide if they want to participate in the pregnancy-adapted ICBT-program (only possible if 10 or more weeks left till estimated delivery date), start the regular ICBT-program for depression within 2-6 weeks post-partum, or decline ICBT-treatment. The participants in this study will be recruited from all over Sweden via internet, advertisements and information at antenatal clinics. A web-based screening questionnaire will form the basis for a first assessment and review of inclusion criteria, followed by a structured telephone interview where diagnoses (SCID-1 for depression, adjusted for DSM 5, and M.I.N.I. for other diagnoses and assessment of suicide risk) and suitability will be assessed, a CGI-rating will be performed, and the final decision on inclusion will be made. Level of depression pre- and post-treatment will be assessed with MADRS-S filled out via the internet-treatment platform together with the other self-rating measures used in the main study. A questionnaire where the participants evaluate the content of the adapted ICBT-program and their own use and perceived benefit of the treatment methods will also be given at post-treatment and during treatment. Structured telephone interview will be held at post-treatment, primarily to assess the content of TAU, to administer CGI and a standardized version for MADRS-S (designed to replace missing questionnaire data), and to make a qualitative evaluation of the participants view of the adapted ICBT-program. The estimated effect of ICBT compared to TAU is 0.8 (Cohen's d) and with 60 participants and some attrition this will result in a statistical power of 80% for this initial, smaller RCT.

Interventions

BEHAVIORALICBT for antenatal depression

Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform

OTHERTAU

Treatment as usual provided at antenatal clinics and other health care instances

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* pregnant female \> 18 years old at gestational week 11-28 * verified moderate depression according to SCID-I with or without concomitant anxiety disorder * able to understand the Swedish language orally and in written * able to use the internet for the ICBT * currently in contact with an antenatal clinic to receive regular care

Exclusion criteria

* known drug or alcohol abuse * serious somatic disorder or psychiatric disorder such as psychosis, bipolar disorder, severe personality disorder, autism or mental retardation and severe melancholic or psychotic depression, * having started or changed medication with SSRI, SNRI or mood-stabilizers within 3 weeks, * according to psychiatric assessment have a high suicide risk will be excluded from the study. These women will be helped to receive necessary psychiatric treatment as usual.

Design outcomes

Primary

MeasureTime frameDescription
Self-rated depression measured by Montgomery Asberg Depression Rating ScaleChange from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partumDepression measured by Montgomery Asberg Depression Rating Scale (MADRS-S), a 9-item self-rated measure of change in depression severity. It also screens for suicidality.

Secondary

MeasureTime frameDescription
Self-rated function Work and Social Adjustment ScaleChange from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partumWork and Social Adjustment Scale (WSAS; Zahra et al., 2014)
Self-rated Insomnia Insomnia Severity IndexChange from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partumInsomnia Severity Index (ISI; Bastien, Vallieres & Morin, 2001)
Self-rated antenatal depression Edinburgh Postnatal Depression ScaleChange from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partumEdinburgh Postnatal Depression Scale (EPDS; Cox, Holden & Sagovsky, 1987)
Self-rated anxiety and worry GAD-7Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partumGAD-7(Beard, & Björgvinsson, 2014)
Expert rating of overall disease burden Clinical Global Impression - Severity scaleChange from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partumClinical Global Impression - Severity scale (CGI-S; Guy, 2000)
Self-rated function/quality of life EuroqolChange from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partumEuroqol (EQ-5D ; Hinz et al., 2006),

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026